Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05719207
Other study ID # REB22-1601
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 25, 2023
Est. completion date December 30, 2024

Study information

Verified date October 2023
Source University of Calgary
Contact Jaimi Workun
Phone 403-764-4755
Email jaimi.workun@albertahealthservices.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is being conducted to learn more about a procedure, balloon dilation of the eustachian tube, in treating patients with eustachian tube dysfunction. Traditionally, eustachian tube dysfunction is treated with nasal steroid sprays and decongestants, or by placement of ear tubes. However, current evidence suggest that medical options are ineffective, and placement of ear tubes is not risk-free. The investigators are carrying out this research study with the following goals: 1. Determine if balloon dilation of the eustachian tube is superior to a placebo procedure in treating patients with eustachian tube dilatory dysfunction 2. Identify patient variables associated with positive response to balloon dilation of the eustachian tube 3. Re-demonstrate the safety of balloon dilation of the eustachian tube What does participation in this study involve? Participants in this study will: - Agree to be randomly assigned to undergo either: balloon dilation of the eustachian tube, or a placebo procedure, with the option to undergo dilation of the eustachian tube 6 weeks later - Agree to allowing the investigators access to their personal health information - Complete the following assessments and questionnaires in clinic before undergoing balloon dilation or placebo procedure: - A questionnaire to assess your eustachian tube dysfunction - An assessment of the movement of your ear drum (tympanogram) - A hearing test (audiogram) - A questionnaire to assess the impact of eustachian tube dysfunction on work/activity - A questionnaire to assess overall health-related quality of life - An assessment of the ability to equalize middle ear pressure(s) - Visual examination of the ear drums - Repeat the above assessments and questionnaires over the course of four follow-up appointments at 6-, 12-, 24-, and 52-weeks after the procedure.


Description:

Adult eustachian tube dilatory dysfunction (ETDD) accounts for over 2 million healthcare visits annually. It can cause longstanding negative middle ear pressure which may lead to otitis media with effusion, tympanic membrane retraction, perforation, middle ear atelectasis and cholesteatoma. Despite this, effective treatments for ETDD are unavailable. Recently, balloon dilation of the eustachian tube (BDET) has gained popularity, where the cartilaginous portion of the Eustachian tube undergoes local dilation with balloon inflation. This technique underwent industry-funded clinical trials in the United States demonstrating its safety and it's superiority to medical management. However, these studies are confounded by industry funding and lack of a blinded control group, the latter of which is critical in a condition where patient-reported outcome measures are relied on. Furthermore, the randomized studies to date do not include patients with baro-challenge ETDD, where symptoms are limited to the context of ambient pressure changes. As such, the investigators opted to perform a non-industry-funded, placebo-controlled trial including both chronic and baro-challenge ETDD patients in a Canadian setting. Potential participants will be identified as possible study candidates with either chronic ETDD or baro-challenge ETDD, who have failed conservative management. At baseline, participants would undergo pure tone audiometry, tympanometry, and otoscopy. An ETDQ7, ad hoc work/activity impairment questionnaire, and EQ-5D-5L questionnaire would be completed. The patient's ability to equalize their middle ear pressure would be assessed by direct visualization of the tympanic membrane as the patient equalizes their middle ear pressure. For patients with baro-challenge ETDD, a baseline ad hoc questionnaire to quantify their symptoms will be completed as well. Patients would then be randomized into BDET versus placebo groups. Patients in the experimental group undergoing BDET in-office will undergo dilation after anxiolytic pre-medication, nasal decongestion, as well as topical anesthesia of the lateral tympanic membrane, the eustachian tube orifice, and the nasal cavity. Patients randomized to the placebo group would undergo a similar procedure in-office, but without dilation of the eustachian tube. Patients in the experimental group with contraindication to in-office BDET will undergo BDET under general anesthetic in an operating room setting. The participants' first follow-up visit with the surgeon is at 6 weeks post-procedure, where patients in the placebo control group would be offered the option to cross-over into the BDET group. Follow up would also be repeated at 12 weeks, 24 weeks, and 52 weeks post-procedure.


Recruitment information / eligibility

Status Recruiting
Enrollment 76
Est. completion date December 30, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria (Chronic ETDD): - >3 months of symptoms of ETDD (otalgia, ear pressure, muffled hearing, tinnitus, cracking or popping, feeling clogged) persistent at enrollment - Persistence of symptoms despite >4 weeks INCS or >7d course of systemic steroid within 6 months from enrollment - Documented Type B or C tympanogram at or within 6 months from enrollment - ETDQ7 = 2.1 at enrollment Inclusion criteria (baro-challenge ETDD): - >12 months of baro-challenge induced symptoms occurring at least every 4 months within the past year - Symptoms include otalgia, ear pressure, muffled hearing, tinnitus, cracking or popping, feeling clogged, vertigo, or facial nerve palsy, which resolve within 3 days of pressure equalization. - Failure of at least one of: topical/oral decongestant, pneumatization device, and/or pressure relief ear plugs. Exclusion Criteria: - Signs/symptoms of patulous eustachian tube dysfunction (autophony, tympanic membrane movement with breathing) - Adjunctive surgical procedure needed (ex. septoplasty, tympanostomy tube) - Presence of a tympanic membrane (TM) perforation or tympanostomy tube - Fluctuating SNHL, AOM, grade IV TM retraction, or tympanosclerosis of >50% of the TM - Uncontrolled sino-nasal disease, reflux, TMJ disorder, immunodeficiency, or allergies - Known ICA dehiscence of the bony ET of the symptomatic ear - Recent head and neck surgery within the past 3 months or planned procedure during study - History of radiation to the head and neck - History of craniofacial abnormality - Prior ET intervention - Psychiatric condition or cognitive impairment which precludes capacity to consent.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Balloon dilation of eustachian tube (Stryker XprESS LoProfile ENT dilation system)
Patients in the intervention group would undergo balloon dilation of the eustachian tube under local anesthetic in clinic. The Stryker XprESS LoProfile ENT dilation system will be used. Participants may undergo dilation under general anesthesia if a contraindication to in-clinic dilation exists.
Other:
Sham procedure
Patients in the sham group will undergo the motions of an in-office dilation of the eustachian tube, without actually dilating the eustachian tube.

Locations

Country Name City State
Canada Otology Clinic, Clinic 7A, South Health Campus Calgary Alberta
Canada Sunnybrook Health Sciences Center Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
University of Calgary

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in mean Eustachian Tube Dysfunction Questionnaire (ETDQ7) score Score range 1-7, with higher score indicating more severe symptoms 6 weeks, 12 weeks, 24 weeks, and 52 weeks post-intervention
Primary Change in symptoms (ad hoc baro-challenge ETDD symptom questionnaire) Composite of quantitative and qualitative data points 6 weeks, 12 weeks, 24 weeks, and 52 weeks post-intervention
Secondary Change in tympanogram type and pressure at peak compliance Change from type C to A or type B to C or type B to A is considered improvement, and vice versa is considered deterioration. Pressure at peak compliance (continuous variable, where a value of zero is normal, and more negative values indicate worse ET function). 6 weeks, 12 weeks, 24 weeks, and 52 weeks post-intervention
Secondary Change in audiogram (pure tone average thresholds) Pure tone average thresholds measured at 500hz, 1khz, 2khz, 4khz, 6khz, and 8khz, where values below 25dB are normal, and higher values indicate worse hearing. Air-bone gap at 500hz, 1khz, 2khz, 4khz where normal value is 0dB, and higher values indicate worse conductive hearing. 24 weeks
Secondary Improvement in ability to equalize middle ear pressure Qualitative measure where inability to equalize middle ear pressures is a negative outcome. 6 weeks, 12 weeks, 24 weeks, and 52 weeks post-intervention
Secondary Tympanic membrane position on otoscopy Qualitative measure where the tympanic membrane will be in a normal position, or in an abnormal retracted position. 6 weeks, 12 weeks, 24 weeks, and 52 weeks post-intervention
Secondary Ad hoc work/activity impairment questionnaire score Score range 1-7, with higher score indicating more severe symptoms 6 weeks, 12 weeks, 24 weeks, and 52 weeks post-intervention
See also
  Status Clinical Trial Phase
Completed NCT04776967 - Effect of Total Compression Time and Rate (Slope) on Incidence of Symptomatic ETD and MEB: A Phase II Prospective Study. N/A
Recruiting NCT04804098 - Effect of Rate (Slope) of Compression on the Incidence of Symptomatic ETD and MEB: a Phase III Prospective Study. N/A
Terminated NCT01974726 - Gas Supply, Demand and Middle Ear Gas Balance -- Diagnosis of Eustachian Tube Dysfunction N/A
Recruiting NCT05600595 - The Evaluation of Eustachian Tube Function and Its Influencing Factors After Snoring Operation in Children
Not yet recruiting NCT05998356 - Long-term Assessment of Balloon Eustachian Tuboplasty for Obstructive Eustachian Tube Disease N/A
Not yet recruiting NCT03322579 - Balloon Dilation of the Eustachian Tube, a Lower Pressure Challenge N/A
Withdrawn NCT03886740 - Tympanostomy Tubes Versus Eustachian Tube Dilation N/A
Completed NCT04809753 - Eustachian Tube Dilation With an Endovascular Balloon N/A
Withdrawn NCT02631187 - Feasibility Study of Balloon Eustachian Tuboplasty (BET) N/A
Completed NCT04902963 - What is the Tympanic Membrane Healing Time After Insertion of a Gelfoam PE Tube? N/A
Completed NCT04136977 - XprESS ET Registry
Completed NCT03197558 - Adult Study to Evaluate Placement of Tympanostomy Tubes In-office (ADEPT) Phase 2
Completed NCT01251432 - Risk Factors and Potential Causes of Eustachian Tube Dysfunction in Adults N/A
Recruiting NCT05055115 - Ph.D.-Project: Eustachian Tube Dysfunction: Causes, Diagnosis, Treatment, and Prognosis N/A
Recruiting NCT04645511 - Balloon Sinuplasty Efficiency in Maxillary Rhinosinusitis. N/A
Not yet recruiting NCT05222230 - FFP3 Respirators and Ears - Effects on Middle Ear Pressure and Hearing N/A
Completed NCT02667301 - Eustachian Tube Dysfunction Assessment N/A
Not yet recruiting NCT05229380 - Pretympanoplasty Assessment of Patency and Mucociliary Function of Eustachian Tube
Completed NCT03850197 - Tubomanometry and EarPopper Devices for Eustachian Tube Function Testing
Terminated NCT05270031 - Balloon Dilation of the Eustachian Tube N/A